Sameeh M. Salama, Ph.D. is the Vice President of Business Development at NAEJA Pharmaceutical Inc. His responsibilities include all activities related to in-licensing and out-licensing of research projects, strategic planning, project design and monitoring, as well as contract research sales and marketing. Dr. Salama joined the Edmonton-based biotechnology company SynPhar laboratories Inc. in 1994 as Group Leader then Director of the Microbiology group to work on projects related to the discovery of new antibiotics. After the transition of SynPhar into NAEJA in 1999 he was appointed as Senior Director then Vice President of Business Development. Dr. Salama was heavily involved in completing the recently announced $750 million licensing agreement between F. Hoffmann la Roche, Meiji-Seika and Fedora Pharmaceuticals Inc.
Dr. Salama received his Ph.D. in Medical Microbiology from the University of Salford, UK and has published over 50 original research articles and presentations at international congresses and has 6 original patents in the infective and inflammatory disease areas.